



RESEARCH ARTICLE

Potential cost-effectiveness of childhood screening for type 1 diabetes: Examining reducing Diabetic Ketoacidosis at diagnosis and long-term outcomes to assess the justifiable cost per child screened.

[version 1; peer review: awaiting peer review]

Daniel J Pollard ¹, Rachel E J Besser^{2,3}, Colin Dayan⁴, Julia Townson⁵, Harjinder Singh⁶, Rosemary Greenwood⁷, Andrew Farmer ⁸, Paul Aveyard⁸, Alan Brennan ¹

¹Sheffield Centre of Health and Related Research (SCHARR), School of Medicine and Population Health, The University of Sheffield, Sheffield, S1 4DA, UK

²JDRF/Wellcome Diabetes and Inflammation Laboratory, Centre for Human Genetics, Nuffield Department of Medicine, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, England, UK

³Department of Paediatrics, University of Oxford, Oxford, UK

⁴Centre for Human Genetics, University of Oxford, Oxford, UK

⁵Centre for Trials Research, Cardiff University, Cardiff, UK

⁶Patient and Public Involvement Investigator, London, UK

⁷Department of Health Sciences, University of York, York, England, UK

⁸Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England, UK

V1 First published: 16 Sep 2025, 5:80
<https://doi.org/10.3310/nihropenres.14026.1>

Latest published: 16 Sep 2025, 5:80
<https://doi.org/10.3310/nihropenres.14026.1>

Open Peer Review

Approval Status *AWAITING PEER REVIEW*

Any reports and responses or comments on the article can be found at the end of the article.

Abstract

Introduction

Diabetic ketoacidosis (DKA) life-threatening emergency that occurs in 38% of children with newly diagnosed type 1 diabetes (T1D) in England and Wales. We conducted a cost-utility analysis to assess the potential cost-effectiveness of a childhood T1D screening program for children aged 4 years in England and Wales compared with no screening to reduce the incidence of DKA at T1D diagnosis.

Methods

We developed a decision tree economic model that included the probability of having T1D, the probability that each child with T1D had DKA at diagnosis, and long-term costs and quality-adjusted life years

(QALYs) using general population norms and an adapted version of the Sheffield T1D policy model that did not model the incidence of diabetes-related complications in children aged under 18 years. We tested a screening program that reduced the incidence of DKA at the time of diagnosis by 80%. We calculated the cost of a screening program to provide an incremental cost-effectiveness ratio of £20,000 per QALY gained compared to no screening. We conducted several scenario analyses to test the effects of different data sources and the additional benefits of screening for children with T1D.

Results

For a screening program that reduced DKA by 80%, we showed that the maximum that could be spent on testing and follow-up for children with positive results is £3.17 per child screened. If preventing DKA at diagnosis also improved long-term glycemic control (modelled as a reduction in glycated hemoglobin (HbA1c) of 0.5% (5 mmol/mol)), the maximum could be spent to £23.29 - £56.74, depending on how long improved glycemic control was maintained.

Conclusions

A general population screening program for T1D that only reduces the risk of DKA at diagnosis is unlikely to be economically feasible unless DKA reduction or screening has long-term benefits, such as delaying T1D or persistently lowering HbA1c.

Plain English Summary

We developed a mathematical economic model to determine whether it would be feasible to screen all children in the general population for type 1 diabetes, assuming that the only benefit to children who had type 1 diabetes would be a lower chance that their diabetes would present in a medical emergency called diabetic ketoacidosis. We tested the sensitivity of the model to other key inputs, including screening, causing greater clinical benefits, such as an improvement in the children's type 1 diabetes blood sugar over their lifetime, which would be expected to lower their risk of developing serious complications associated with their diabetes. We found that if screening was associated with only preventing diabetic ketoacidosis at diagnosis of type 1 diabetes, then we would have to develop a screening program that cost less than £3.17 per child in the general population screened for it to be a good use of NHS resources. This would need to cover all invitations, testing, and follow-up costs for children who receive a positive test result in the screening program. However, this did increase in our scenarios, where blood sugar was improved by screening for children with type 1 diabetes and where the probability that diabetic ketoacidosis caused deaths was significantly higher. This indicates that addressing the rate of death for children with diabetic ketoacidosis at diagnosis of type 1 diabetes and whether screening or preventing diabetic ketoacidosis at

diagnosis can lead to an improvement in blood sugar over the lifetime of children with type 1 diabetes, in addition to how effective general population screening is at preventing diabetic ketoacidosis at diagnosis, are all key to establishing whether screening for type 1 diabetes would be a good use of NHS resources.

Keywords

Type 1 Diabetes, Population Screening, Health Economics, Cost-Effectiveness

Corresponding author: Daniel J Pollard (d.j.pollard@sheffield.ac.uk)

Author roles: **Pollard DJ:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Besser REJ:** Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Dayan C:** Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Validation, Writing – Review & Editing; **Townson J:** Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Writing – Review & Editing; **Singh H:** Conceptualization, Funding Acquisition, Investigation, Writing – Review & Editing; **Greenwood R:** Methodology, Validation, Writing – Review & Editing; **Farmer A:** Conceptualization, Funding Acquisition, Investigation, Writing – Review & Editing; **Aveyard P:** Conceptualization, Investigation, Writing – Review & Editing; **Brennan A:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Supervision, Validation, Visualization, Writing – Review & Editing

Competing interests: DP and AB worked on the Hypo-RESOLVE project, which received in-kind support from Novo Nordisk, Eli Lilly, Sanofi-Aventis, Abbott and Medtronic. All other authors declare no conflicts of interest.

Grant information: This project is funded by the National Institute for Health Research (NIHR) under its [‘Research for Patient Benefit (RfPB) Programme’ ((Award ID: NIHR203948). AF was supported by the NIHR Oxford Biomedical Research Center.]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2025 Pollard DJ *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Pollard DJ, Besser REJ, Dayan C *et al.* **Potential cost-effectiveness of childhood screening for type 1 diabetes: Examining reducing Diabetic Ketoacidosis at diagnosis and long-term outcomes to assess the justifiable cost per child screened. [version 1; peer review: awaiting peer review]** NIHR Open Research 2025, 5:80 <https://doi.org/10.3310/nihropenres.14026.1>

First published: 16 Sep 2025, 5:80 <https://doi.org/10.3310/nihropenres.14026.1>

Introduction

Type 1 diabetes (T1D) is a common long-term condition, with 32,809 children and young adults in England and Wales receiving care at pediatric diabetes units in 2023/24¹. T1D results from the autoimmune destruction of pancreatic beta cells and requires lifelong replacement with the deficient hormone insulin via multiple daily injections or insulin pump therapy. At diagnosis, nearly all children present with symptoms needing urgent insulin treatment and hospital admission, with 38% in the life-threatening state of diabetic ketoacidosis (DKA)². DKA is associated with shock and neurocognitive deficits and has also been associated with long-term hyperglycemia, a known predictor of adverse long-term health outcomes through the development of macrovascular (e.g., myocardial infarction (MI), stroke, heart failure) and microvascular complications (e.g., foot ulcers, blindness, renal disease) of T1D^{3–5}. There is potential for earlier detection through screening because T1D develops before symptom onset, with well-recognized stages, hallmarked by the onset of two or more islet-specific autoantibodies with the presence of normoglycaemia (stage 1), dysglycemia (stage 2), and symptomatic type 1 diabetes (stage 3)⁶.

The majority (> 85%) of children presenting with T1D and those who present with DKA do not have a family history of the disease⁷. This means that, to make a meaningful difference in the early identification and prevention of DKA, a general population screening strategy would need to be implemented. Outside of the UK, T1D screening approaches in both the general population and higher-risk populations (e.g., children with T1D genes that are associated with a higher risk of developing T1D or having first-degree relatives with T1D) have demonstrated that early detection of T1D has clinical benefits. In Germany, when more than 90,000 children aged 1.75–5.99 were screened for T1D, 280 (0.31%) had presymptomatic type 1 diabetes⁸. The TEDDY study found that a cohort who was identified and intensively monitored had a statistically significantly lower probability of presenting with DKA at diagnosis (11.3%) in some similar cohorts of children who did not receive this follow-up (36.4%, 25.3%), but not others (16.9%, 18.7%)⁹. If DKA at diagnosis could be prevented, this would mean that children with T1D do not need to be hospitalized at the start of insulin treatment, they present earlier with a lower glycated hemoglobin and higher residual pancreatic function (C-peptide), making the disease easier to manage and more available for disease-modifying therapies^{10,11}.

In the UK, the National Screening Committee (NSC) requires scientific evidence for a proposed screening program, including the accuracy of the test, benefits of early detection to improve outcomes, any harm or side effects associated with the test or treatments, whether it would significantly improve overall health in the population, and most relevant to this study—cost-effectiveness: would screening be a good use of healthcare resources? If the benefits of screening cannot be obtained at an acceptable cost, it is unlikely that the NSC would consider screening for T1D¹². Consequently, developing an

early economic analysis can inform us whether screening that prevents DKA is potentially economically viable. If it is not, what other benefits would screening for T1D have for children identified as having T1D for screening to be cost-effective? This helps inform what research should be conducted on the benefits of screening in the future to establish whether screening for T1D is cost-effective.

We conducted a cost-utility analysis of a potential general population-screening program for T1D in England and Wales. Given that definitive randomized controlled trials do not currently exist, we calculated the screening programme could cost per child screened in the general population to obtain an Incremental Cost-Effectiveness Ratio (ICER) of £20,000 per quality-adjusted life year (QALY) gained. We explored several scenarios of differing treatment effects associated with general population screening for T1D.

Methods

Patient and Public Involvement

A PPI group of parents (1 one whom did not have experience of T1D) was established prior to submitting the bid, and the group was involved throughout. The parent of a child diagnosed with T1D was a full member of the project management group and contributed to the design of the economic analyses. The results of the economic analysis were then presented to a group of parents with T1D.

Health economic analysis plan

A health economic analysis plan was not developed for this work.

Population

Our population was the general population of children aged 4 years because we believed that this would be the optimal age for a single screen test, and if implemented, this could be done at the same time as the pre-school vaccination in the UK. The general population comprised 50% males. The population diagnosed with T1D was assumed to be 52% male based on National Paediatric Diabetes Audit (NPDA)¹³.

Setting, perspective, Discounting and time horizon

Our study used the English and Welsh NHS setting. Consequently, we followed the National Institute for Health and Care Excellence (NICE) guidelines and took an NHS and personal social services perspective, discounted future costs and QALYs at 3.5% per annum, and took a lifetime horizon¹⁴.

Intervention

The intervention considered was a screening test to detect T1D in every child in England and Wales, aged 4. To detect T1D in the general population, we assumed that the screening program would perform identically to the screening program presented by Ziegler *et al.* in Germany⁸.

Comparator

The comparator was no screening for T1D (current practice).

Selection, measurement and valuation of outcomes

QALYs were the key measures of benefits and harm. The key benefits of screening included prevention of DKA at diagnosis and potential long-term benefits from preventing DKA at diagnosis in scenario analyses.

For our base case, we applied a hazard ratio to reduce the probability of DKA presentation compared with the control arm.

Utilities for health states in the model were sourced from the literature with values based on the EQ-5D self-reporting by populations of interest, valued using the England and Wales EQ5D3L value set, which were preferred in line with NICE guidance^{15–17}.

Currency, price data and conversion

All costs in the economic model are in pounds sterling and are 2020/21 prices. The costs from previous price years were inflated to 2020/21 prices using the NHSCII inflation index¹⁸.

Rationale and description of model logic

Figure 1 shows the decision-tree structure for a single strategy (screening or no screening). The population enters the model and is assigned as either truly having T1D or not having T1D. For the population subgroup without T1D, their quality-adjusted life expectancy was estimated using Office for National Statistics (ONS) lifetables to estimate their life expectancy and age-gender norms for utility^{19,20}. For the population with T1D, we assumed for simplicity that they developed T1D immediately. The population subgroup with T1D was split into two further subgroups, one who developed DKA at the time of diagnosis and the other who did not. In the screening arm, a lower probability of having DKA is applied than in the no-screening arm; in the base case, this is the only benefit of

screening. Then, the proportion of the population present in the DKA is assumed to be present immediately and can either survive or die from the DKA. Therefore, fewer children with T1D will die if they undergo screening, as fewer of these children have DKA. As they develop T1D immediately, this means that our estimates will be slightly favorable to screening, as the costs and utility decrements due to DKA will not be discounted because they occur in the future. The probability of death is taken from the NPDA in the base case. For the proportion of the population that has a DKA at diagnosis, every child was assumed to have an admission for their DKA, and an associated cost was added to their overall costs of treatment¹⁹. For the proportion of the population that has T1D and survives (either with or without an initial DKA at diagnosis), their estimated lifetime costs and QALYs are estimated using a modified version of our individual-level simulation model designed to estimate outcomes for adults with T1D²¹. In the base case, these projections of lifetime costs and QALYs are the same in both the screening and no screening arms. Scenarios of long-term benefits of HbA1c, severe hypoglycemia, and future DKA (which will change the projected lifetime costs and QALYs for children with T1D) were explored in scenario analyses.

In a decision tree, the expected probability that each outcome occurs is multiplied by the expected costs and QALYs of that outcome to generate the expected outcome. All expected outcomes are added together to provide the overall expected costs and QALYs.

Analytics, assumptions and study parameters

Clinical probabilities

A summary of the clinical probabilities used in the economic model is presented in Table 1. Detailed descriptions of the evidence base are provided in the subsequent sections.




Figure 1. The model diagram for a single strategy (either screening or no screening).

Table 1. A summary of the clinical parameters in the economic model.

Parameter	Value	Source
Probability that a child without T1D is male	50%	Assumption
Probability that a child with T1D is male	52%	NPDA, proportion of children with newly diagnosed T1D who were male with an age of diagnosis between 4 and 18 ¹³
Probability (proxied by cumulative incidence) of T1D post screening	0.31% (280/90632)	Ziegler <i>et al.</i> ⁸
If a child has T1D, the probability of having a DKA at diagnosis for current practice	38.5%	NPDA, 2019/20 data ²²
Hazard ratio for the effect of screening on the incidence of DKA at diagnosis	0.2	Assumption used in a power calculation for a proposed trial of general population screening programme for T1D
If a child has T1D, the probability of having a DKA at diagnosis for children who are screened	9.3%	Calculated based on probability for current practice and the hazard ratio*
Probability of death from DKA at diagnosis	0.03% (4 / 14363)	NPDA ^{22,23}

T1D, type 1 diabetes; NPDA, national paediatric diabetes audit

*, the calculation to produce this number is as follows

1) Hazard of DKA at diagnosis no screening = $-(\ln(1 - \text{probability of DKA at diagnosis}))$

2) Hazard of DKA at diagnosis screening = Hazard of DKA at diagnosis no * Hazard Ratio

3) Probability of DKA at diagnosis screening = $1 - \exp(-\text{hazard of DKA at diagnosis screening})$

Probability of having T1D

We used the study by Zeigler *et al.*, which was a prospective cohort study of screening in the general population of children aged 1.75–6 years in Bavaria, Germany⁸. They found that 0.31% of their population developed T1D. We assumed that this percentage would be relevant for screening individuals aged 4 years in England and Wales. This is based on age 4 being approximately in the middle of this age range, clinical advice, and the fact that the study was conducted in Germany, which we would expect to be similar to an English and Welsh setting⁸.

Probability of having a DKA at diagnosis, if the child has T1D

Based on the most recent NPDA data for 2019/20, we assumed that in the absence of screening, 38.5% of children with T1D would have a DKA event at their diagnosis²². For children who were screened, we assumed that there would be an 80% reduction in their risk of having a DKA at diagnosis (this is implemented as a Hazard Ratio of 0.2, as we expected this evidence to be generated in a time-to-event analysis). This was sourced from our early work that performed power calculations for subsequent randomized controlled trials of screening, with DKA prevention as the primary endpoint. This was based on the observed effectiveness. This gave the probability that a child who was screened and developed T1D would have DKA at a diagnosis of 9.3%.

Probability of dying from DKA at diagnosis

From the most recent NPDA report on childhood outcomes, there were four deaths related to DKA (but not specifically DKA at diagnosis) in children aged 0–14 between 2015–20²³. In the

NPDA, 14,363 DKA events were detected over this period²². This gives a 0.03% conditional probability that a child, given that they have a DKA at diagnosis, could die from this event.

Decision tree outcomes

People without T1D

For people without T1D, we estimated their life expectancy from the Office for National Statistics (ONS) life table mortality data¹⁹. To get their utilities, we used values reported by the NICE decision support unit (DSU) by age and gender for the English and Welsh population²⁰. As the NICE DSU data is only valid for adults, we assumed that all children would have the same utility as a 16 year old from this analysis. These data were combined to estimate the expected QALYs of this population. This gave a predicted life expectancy of 77.30 years, when applying utilities were applied, a total quality-adjusted life expectancy of 67.02 QALYs, when discounted, was applied at 3.5% per annum, which gave a discounted quality-adjusted life expectancy of 24.61 QALYs.

People with T1D, who die from a DKA at diagnosis

We assumed that the death caused by DKA occurred on the day of diagnosis. Therefore, we included people who died from DKA at a diagnosis of 0 QALYs.

This incurs a treatment cost for the treatment of DKA. This was £3,278, which was obtained from the National Schedule of Reference Costs²⁴, Currency Code PK67A (Paediatric Diabetes Mellitus, with Ketoacidosis or Coma, with CC Score 1+) and PK67B (Paediatric Diabetes Mellitus, with Ketoacidosis

or Coma, with CC Score 0). This was estimated as a weighted average from all the times these currency codes were used in 2020–21.

People with T1D who do not die from DKA at diagnosis

To reflect the expected costs and QALY outcomes of our population we conducted a run of our Sheffield Type 1 Diabetes Policy model²¹. This model was run using 2015/16 prices and then the total discounted costs over an average child with T1D's life expectancy was inflated to 2020/21 prices.

In this analysis, we used our baseline characteristics from the NICE guidelines for modelling CGM in adults and did not allow any risk factors to change over time. We set the age to 4 and the proportion of males to 52% based on NPDA data:

The probability of having subsequent DKAs and severe hypoglycemia was taken from NPDA data on the probability of having a DKA or severe hypoglycemic event by diabetes duration²². We assumed that one event occurred per person per year, due to the absence of information on the number of events that occurred per year. We assumed that the probability of having DKAs in the group with the highest diabetes duration in the dataset was maintained for the rest of the patient's lifetime.

We adapted our model so that simulated individuals could not develop diabetes-related complications (cardiovascular disease,

retinopathy, macular edema, neuropathy, or nephropathy) until they were 18. The model estimated lifetime costs and QALYs for this population. We took annual costs for managing T1D from evidence submitted to NICE as part of their appraisal of hybrid closed-loop technology (TA943, £5,387 per year on insulin and devices and £575 per year for contacts with health care professionals)²⁵.

In addition, the cost of presenting with DKA at diagnosis and a utility decrement associated with DKA (for children who survived their DKA at diagnosis) were also included, which was done in our decision tree and not in the long-term model being used to generate quality-adjusted life expectancy. A summary of the expected lifetime discounted costs and QALYs for these children with T1D are given in Table 2 and a summary of the baseline characteristics used in the Sheffield T1D model are given in Table 3.

People with T1D

The assumptions on costs and QALYs incurred by this population group were the same as those of the population with T1D who did not die from DKA at diagnosis; however, they did not incur the cost of treating their DKA at diagnosis or the associated utility decrement.

Economic analysis

We ran our analysis without any assumed costs for screening, as it is too early at this stage to estimate the cost of a general

Table 2. Summary of the economic outcomes used in the model.

Parameter	Value	Source
Discounted lifetime QALYs lived for a child with no T1D	24.61	ONS life tables ¹⁹ , Hernández-Alava <i>et al.</i> ²⁰
Costs for children with no T1D, excluding screening	£0	Assumption, as only T1D specific costs are in economic analyses in the England and Wales.
Discounted lifetime QALYs lived for a child with T1D, no DKA at diagnosis	20.001	Calculated for this study using an adapted version of the Sheffield Type 1 Diabetes Model for adults with T1D ²⁶
Costs for children with T1D, no DKA at diagnosis (discounted over lifetime)	£201,088	Adapted version of the Sheffield Type 1 Diabetes Model for adults with T1D ²⁶
Utility change associated with DKA	-0.0091	Peasgood <i>et al.</i> ²⁷
QALYs lived for children with T1D, DKA at diagnosis, died	0	Assumption
NHS Costs for children with T1D, DKA at diagnosis, died	£3,278	NHS reference costs for treating paediatric DKA – Activity Weighted Average of Currency Codes PK67A and PK67B ²⁴
QALYs for children with T1D, DKA at diagnosis, survive	19.992	Calculated for this study using an adapted version of the Sheffield Type 1 Diabetes Model for adults with T1D + utility change associated with DKA
Costs for children with T1D, DKA at diagnosis, survive	£204,366	Adapted version of the Sheffield Type 1 Diabetes Model for adults with T1D + an additional cost for DKA at diagnosis from NHS reference costs for treating paediatric DKA – Activity Weighted Average of Currency Codes PK67A and PK67B ²⁴

T1D, type 1 diabetes, ONS, office for national statistics

Values used in scenario analyses are provided in the supplementary material

Table 3. A summary of the baseline characteristics that were used.

	Mean	Standard Deviation	Source
Baseline Characteristics			
Age	4	Fixed	Target population
Probability that a child with T1D is male	52%	Fixed	NPDA ¹³
HbA1c (%)	9.1	1.7	NICE ²⁸
SBP (mmHg)	131.3	16.3	NICE ²⁸
LDL (mmol/L)	1.3	0.42	NICE ²⁸
HDL (mmol/L)	0.74	0.19	NICE ²⁸
Triglycerides (mmol/L)	0.28	0.2	NICE ²⁸
Ethnicity	White	N/A	NPDA ¹³ - predominant ethnic group out of White, Black or Hispanic (ethnic groups used in our model)
Other key model parameters			
Ongoing annual cost of diabetes treatments	£5,387	HCL cost is from NICE TA943, (Final Appraisal determination committee papers, EAD addendum, Table 16) ²⁹ + annual insulin costs from Asgharzadeh <i>et al.</i> (page 199) ³⁰ . Costs were deflated to 2015/16 prices to match the other costs in the model using the NHSCII pay and prices index ³¹ .	
Ongoing annual cost of diabetes related contacts	£575	Annual cost of ongoing hospital visits from Asgharzadeh <i>et al.</i> (page 200) ³⁰ . Costs were deflated to 2015/16 prices to match the other costs in the model using the NHSCII pay and prices index ³¹ .	
Probability of having a DKA event post diagnosis in 2019/20, with a diabetes duration of:			
Under 1 year	1.9%	NPDA ²² , Figure 14	
1 to 2 years	3.9%	NPDA ²² , Figure 14	
3 to 4 years	5.1%	NPDA ²² , Figure 14	
5 to 9 years	6.1%	NPDA ²² , Figure 14	
10+ years	6.2%	NPDA ²² , Figure 14	
Probability of having a hospitalised severe hypoglycaemia event in 2019/20 with a diabetes duration of:			
Under 1 year	3.20%	NPDA ²² , Figure 19	
1 to 2 years	2.60%	NPDA ²² , Figure 19	
3 to 4 years	2.20%	NPDA ²² , Figure 19	
5 to 9 years	1.90%	NPDA ²² , Figure 19	
10+ years	1.80%	NPDA ²² , Figure 19	
Probability that a severe hypoglycaemic event results in a hospitalisation	0.25 (25/101)	Hammer ³² , Table 5	
Parameters for scenario analyses			
Hazard ratio for having a DKA post diagnosis (DKA at diagnosis v no DKA at diagnosis)	0.55	Karges <i>et al.</i> ³³	
Hazard ratio for having a severe hypoglycaemic event (DKA at diagnosis v no DKA at diagnosis)	0.80	Karges <i>et al.</i> ³³	

NICE, National Institute for Health and Care Excellence; NPDA, National Paediatric Diabetes Audit

population screening program for T1D. What we did Instead, we calculated the cost of screening to provide an Incremental Cost-Effectiveness Ratio (ICER) of £20,000 per QALY gained. The ICER is calculated as:

$$ICER_{\text{screening}} = \frac{(\text{Expected Cost of Outcomes}_{\text{screening}} + \text{Expected cost of screening}) - \text{Total Expected Cost}_{\text{No Screening}}}{\text{Expected QALYs}_{\text{screening}} - \text{Expected QALYs}_{\text{No Screening}}}$$

Where the cost of screening itself is not included in the screening costs

We rearranged this to give:

$$\begin{aligned} \text{Expected cost of screening} = \\ \text{£20,000} * (\text{Expected QALYs}_{\text{screening}} - \text{Expected QALYs}_{\text{No Screening}}) + \\ (\text{Total Expected Cost}_{\text{No Screening}} - \text{Expected Cost of Outcomes}_{\text{screening}}) \end{aligned}$$

We used an ICER of £20,000 per QALY gained, as this is usually the lower end of the range of ICERs that the NICE considers acceptable. This provides an upper limit on the cost of screening, given the expected costs associated with T1D and the associated QALYs of people being screened.

Characterizing heterogeneity

No subgroup analyses were explored

Characterising distributional effects

No adjustment was made to reflect the priority populations, as this study concerns the feasibility of general population screening.

Sensitivity of results to effect size on primary outcome

As we were developing an early model to identify key drivers for an economic screening case, we did not include any probabilistic analyses that would be expected in any economic evaluation of an actual screening program. The primary reason for this is that the most important uncertainty relates to the effectiveness of the screening program in reducing the number of people whose first knowledge of T1D is being diagnosed as an emergency in a hospital with a DKA. We do not yet have data on the effectiveness of an English-and-Welsh screening program and the statistical uncertainty in this effectiveness. We conducted a series of scenario analyses to explore the uncertainty in the true values of the model inputs.

Sensitivity of results to other parameters

We conducted 15 further exploratory analyses to explore the scale of the impact of other potential effects of a screening program beyond the DKA at diagnosis. The exploratory analyses were as follows:

- 1) We explored changing the Hazard Ratio for screening between 0.1% and 1 in increments of 0.1. The base case had a Hazard Ratio of 0.2. These were performed as scenarios 1a – 1h.
- 2) Reduced HbA1c in the long-term: A few but not all studies have shown that children who are screened have a long-term improvement in their HbA1c levels. Based on Lungdren *et al.* who showed that HbA1c of

screened children was improved by 0.3% to 0.6% over a 5 year follow up compared to non-screened children in Southern Sweden, we added a -0.5% benefit in HbA1c associated with screening to the our long term economic model³⁴. We did 4 sub scenarios:

- a. A Lifetime effect
 - b. A 40-year effect
 - c. A 30-year effect
 - d. A 20-year effect
- 3) Reduced subsequent DKA and severe hypoglycemia: We added a hazard ratio for the occurrence of future DKA and future severe hypoglycemia, which gives people who had DKA at diagnosis a higher rate of DKA and severe hypoglycemia than those who did not. The HR we used were 0.55 for DKA and 0.80 severe hypoglycaemic events. This was based on Karges *et al.*, who weighted the HR they reported for sporadic and familial diabetes by the proportions of these patients in the baseline characteristics table³³. These were applied for a lifetime. We conducted five scenarios, in which there was a benefit of screening for reducing DKA at diagnosis, as well as the assumption that the other benefits of screening were:
 - a. No effect of screening on HbA1c
 - b. A Lifetime effect of screening on HbA1c
 - c. A 40-year effect
 - d. A 30-year effect
 - e. A 20-year effect
 - 4) Increased mortality rate for a DKA diagnosed child:
 - a. We used data from Gibb *et al.* to determine the probability of dying from DKA instead of NPDA data. They found that out of 628 cases of DKA in their hospital, one patient's death record mentioned DKA as the cause of death. In this scenario, we consequently altered the probability of dying given a person having a DKA from the base case of 0.03% to 0.16% (1/628)³⁵.
 - b. We obtained data from the ONS regarding causes of death by age. We found 80 deaths from endocrine, nutritional, and metabolic diseases (ICD-10 code E00-E90) in 2022 in England and Wales in people aged between 28 days and 14 years. In this scenario, all 80 deaths were assumed to be caused by DKA at diagnosis. The next age band in this data was 15–44, so we did not include data from this age group because almost all people in this group will be adults with T1D. The National Pediatric Diabetes Audit found 3,457 new diagnoses of T1D in children and young people. In this scenario, the probability

of death due to DKA at diagnosis was 2.31% (80/3457).

- 5) The cost of DKA was changed to use the 2021/22 NHS cost collection rather than 2020/21. This changed the cost of DKA to
 - a. £2,457 from £3,278
- 6) Incorporate full NHS cost of diagnosis - Applied a cost of £8,935 to every child who developed T1D and did not die from a DKA at diagnosis, instead of the base case cost of £3,278. This was sourced from McCarroll *et al.*, which is the total NHS and personal social services cost they attributed to in-hospital care for diagnosis of T1D³⁶. This was not included in the main analyses to avoid double counting of DKA at diagnosis cost for children with T1D, who had a DKA at diagnosis and who survived their DKA.
- 7) We set the proportion of patients with T1D to 100%. This is a crude scenario to check whether there is value in preventing DKA at diagnosis if we had a population that solely consisted of children who had or would have T1D.

A summary of the discounted quality-adjusted life expectancy and costs for children with T1D across our conservative and exploratory analyses is presented in [Table 4](#).

Ethics

Ethics approval was not required for this research, as all data were obtained from the published literature.

Results

Summary of the main results

Our results, using only the clinical data that would be generated from an RCT of screening for T1D designed to detect

a difference in the incidence of DKA at diagnosis, are given in [Table 5](#). This shows that in this analysis, we would need the cost of screening to be under £3.17 per child screened (i.e., including the costs for children who do not develop T1D) for a screening program to have an ICER of £20,000 per QALY gained. This is an important threshold for an ICER, as this is the lower end of what NICE usually uses to determine the cost-effectiveness of health technologies and strategies in the English and Welsh NHS, and is also used by the National Screening Committee.

Effect of uncertainty

Our scenario analyses, which explore whether other benefits of screening for children with T1D can be proven, are given in [Table 6](#). [Table 6](#) shows that if we can find other substantial benefits (other than reducing the risk of DKA at diagnosis) from screening for children with T1D, the maximum acceptable cost of screening and follow-up could increase to approximately £50 per child screened. Other scenarios with large impacts on cost-effectiveness include setting the population to all have T1D, increasing the probability of death from DKA, and assuming that all deaths in patients under 14 years of age due to endocrine disorders were due to DKA at diagnosis.

Discussion

Our analyses show that if the only benefit of screening is preventing DKA at diagnosis, then there is very little chance that a general population screening program for detecting T1D would be justifiable on economic grounds, as the maximum screening cost would be in the region of £3.17 per child screened. This average cost would need to cover all aspects of the screening program, including, but not necessarily limited to, inviting all children to be screened, testing the children, and providing support to any children who test positive (including false positives). Any other economic effects not included in the model, for example, overdiagnosis of T1D, would also need to factor into this cost.

Table 4. A summary of the discounted quality adjusted life expectancy and costs for children with type 1 diabetes.

HbA1c effect	NPDA average rates of DKA and SH	Rates of DKA and SH for people with no DKA at diagnosis	Rates of DKA and SH for people with DKA at diagnosis
None – No screening	QALE: 20.001 Costs: £201,088	QALE: 20.005 Costs: £200,108	QALE: 19.998 Costs: £201,772
Lifetime	QALE: 20.431 Costs: £196,687	QALE: 20.435 Costs: £195,683	QALE: 20.428 Costs: £197,374
40 years	QALE: 20.346 Costs: £197,738	QALE: 20.350 Costs: £196,733	QALE: 20.343 Costs: £198,427
30 years	QALE: 20.288 Costs: £198,221	QALE: 20.292 Costs: £197,216	QALE: 20.285 Costs: £198,902
20 years	QALE: 20.159 Costs: £199,353	QALE: 20.163 Costs: £198,360	QALE: 20.156 Costs: £200,038

HbA1c, glycated haemoglobin; NPDA, national paediatric diabetes audit; DKA, diabetic ketoacidosis; SH, severe hypoglycaemia; QALE, quality adjusted life expectancy

Table 5. Results for Justifiable Cost per Child Screened under the conservative base case scenario (assuming an 80% reduction in DKA at diagnosis versus usual care, but no other benefits).

	QALYs	Costs	Incr QALYs	Incr Costs	Justifiable cost per person of Screening for T1D at age 4 at a maximum acceptable ICER of:	
					£20,000 per QALY gained	£30,000 per QALY gained
No Screening	24.5959	£625	-	-	-	-
Screening	24.5959	£622	0.00001	£-2.91	£3.17	£3.31

QALYs, quality adjusted life years; Incr, incremental

Table 6. Scenarios to test the Sensitivity of Results for Justifiable Cost per Child Screened to changing the other effect parameters.

Scenario	Description	Incremental QALYs	Incremental Costs	Maximum per person Cost of Screening at an ICER of £20,000 per QALY gained	Maximum per person Cost of Screening at an ICER of £30,000 per QALY gained
-	Base Case	0.00001	£-2.91	£3.17	£3.31
1a	Screening v No Screening HR on DKA at diagnosis = 0.1	0.00002	£-3.36	£3.67	£3.82
1b	Screening v No Screening HR on DKA at diagnosis HR = 0.3	0.00001	£-2.48	£2.71	£2.82
1c	Screening v No Screening HR on DKA at diagnosis HR = 0.4	0.00001	£-2.07	£2.26	£2.36
1d	Screening v No Screening HR on DKA at diagnosis HR = 0.5	0.00001	£-1.68	£1.84	£1.91
1e	Screening v No Screening HR on DKA at diagnosis HR = 0.6	0.00001	£-1.31	£1.43	£1.49
1f	Screening v No Screening HR on DKA at diagnosis HR = 0.7	0.00000	£-0.96	£1.05	£1.09
1g	Screening v No Screening HR on DKA at diagnosis HR = 0.8	0.00000	£-0.63	£0.68	£0.71
1h	Screening v No Screening HR on DKA at diagnosis HR = 0.9	0.00000	£-0.30	£0.33	£0.35
1i	Screening v No Screening HR on DKA at diagnosis HR = 1	0.00000	£0.00	£0.00	£0.00
2a	Basecase + lifetime HbA1c effect of -0.5% due to screening	0.00134	£-16.51	£43.33	£56.74
2b	Basecase + 40 year HbA1c effect of -0.5% due to screening	0.00108	£-13.26	£34.81	£45.59
2c	Basecase + 30 year HbA1c effect of -0.5% due to screening	0.00090	£-11.77	£29.76	£38.76
2d	Basecase + 20 year HbA1c effect of -0.5% due to screening	0.00050	£-8.27	£18.28	£23.29
3a	S2a + reduced risk of subsequent DKA and severe hypoglycaemia	0.00135	£-18.08	£45.02	£58.49
3b	S2b + reduced risk of subsequent DKA and severe hypoglycaemia	0.00108	£-14.83	£36.51	£47.35

Scenario	Description	Incremental QALYs	Incremental Costs	Maximum per person Cost of Screening at an ICER of £20,000 per QALY gained	Maximum per person Cost of Screening at an ICER of £30,000 per QALY gained
3c	S2c + reduced risk of subsequent DKA and severe hypoglycaemia	0.00091	£13.34	£31.46	£40.52
3d	S2d + reduced risk of subsequent DKA and severe hypoglycaemia	0.00051	£9.81	£19.94	£25.01
3e	Basecase + reduced risk of subsequent DKA and severe hypoglycaemia	0.00002	£4.41	£4.80	£4.99
4a	Use Gibb to inform the probability of death from DKA	0.00004	£2.67	£3.41	£3.78
4b	All deaths in people aged 14 and under in England and Wales due to ICD 10 codes (E00 -E90) are DKA at diagnosis	0.00043	£1.24	£7.28	£11.54
5	Use 21/22 NHS reference costs for DKA cost	0.00001	£2.17	£2.43	£2.57
6	Addition of costs in McCaroll <i>et al.</i> for children with T1D who do not die from DKA at diagnosis	0.00001	£2.91	£3.17	£3.31
7	Population is set to be 100% T1D	0.00429	£941.94	£1,027.65	£1,070.50

The key reason for this is that T1D is rare in the general population and when the benefit of preventing DKA is spread across a whole screening population, this benefit is on average small. If the benefits of screening other than preventing DKA at diagnosis alone can be proven, this could drastically improve the maximum acceptable cost of screening to over £40 per child screened. Incidental findings or screening for multiple conditions could further increase the maximum cost of screening as they may bring additional benefits to the overall screening program.

Strengths and limitations

The key strength of this study is that it addresses the screening costs in England and Wales in various scenarios. This gives us a good idea of what screening could cost in the UK, and what would be the key clinical factors if demonstrated to be the most likely scenario when screening.

Through the scenarios on screening affecting long-term biomedical outcomes, this not only covers scenarios where metabolic control is improved, regardless of the cause. This could be related to preventing DKA at diagnosis or by preventing the psychological trauma of an acute and life-threatening DKA in a previously healthy child. By calculating the mean cost, we could not specify any particular part of the screening design. Therefore, the work is translatable to a variety of potential screening programs with different invitation strategies, tests, follow-up testing schedules, and support programs or interventions to reduce the incidence of DKA for parents and children who test positive for T1D (we do expect that there will be some false positives).

As this was an early analysis, there are many limitations that should be considered when interpreting the results. The key limitations of our study are as follows.

This study does not include the costs or effects of teplizumab, an agent for delaying the onset of stage 3 T1D which is currently undergoing assessment by NICE in a population aged over 8 with stage 2 T1D³⁷. We did not include this, firstly we do expect that many children that would be identified in a screening programme for 4 year olds would remain free of T1D until they were 8, therefore the effects of adding teplizumab are likely to be small.

We have assumed that a screening programme in the UK would achieve exactly the same outcomes as in Ziegler *et al.*⁸ A UK based programme may not have exactly the same outcomes as those in Germany. This means that our current model does not have a natural history component modelling of undiagnosed stage 1, stage 2, and stage 3 T1D in the general population. This implies that we cannot explore different tests for detecting T1D in our current modelling framework.

We have not conducted any primary research; as such, we do not include any utility decrements or increased rates of health care contacts related to psychological distress related to either a child presenting in DKA (to either the parent or the child), or psychological distress related to screening itself. These effects, if shown to exist, should be factored into any cost-effectiveness analysis of screening for type 1 diabetes.

There may be other economic benefits accrued from any health care program that are outside the NHS and personal social

services perspective for economic evaluations set in England and Wales (e.g., preventing time off work for parents as their child is less likely to be present in DKA); however, what is not clear with these benefits is who should pay to gain these benefits (e.g., the parents themselves, their employers, or the government). There may be other economic benefits that are not included because of the absence of evidence. For example, we may be able to evaluate any changes in the psychological burden on the parent/caregiver and the patient.

Because we adopted a decision tree analysis, screening was performed in a snapshot. An actual screening program will have complexities (e.g., time from screening until diagnosis of T1D and testing schedule) that would require a type of model that explicitly includes time in the structure. This may cause changes in the cost and QALYs associated with screening. However, we expect these to be relatively small changes, and we would require extensive epidemiological studies on screening children for T1D in the UK, which currently does not exist.

Our estimates of the expected costs of treating children with T1D are likely to be overestimated. In the NICE appraisal of hybrid closed loops, evidence submitted to this appraisal was used as some of our key costing information for device and treatment costs for T1D, the committee's preferred base case ICER was £104,003 per QALY gained and their acceptable ICER was £20,000 per QALY gained³⁸. As hybrid closed loop is an approved technology in the UK, it is likely that there are commercially confidential arrangements between the device manufacturers and the UK government that effectively lowers the price of HCL from the publicly available prices we used when estimating the discounted lifetime cost of having T1D.

Future research

The key area for future research is to establish whether preventing DKA at diagnosis leads to long-term benefits in children with T1D. This is because it is unlikely that we could design a screening program that costs only an average of £3 per child screened. If these benefits exist, we have a much better chance of designing a screening program that can cost more than £20 per child screened, and if these benefits can be reasonably assumed to be permanent, then the cost per child screened could rise to over £50 per child screened.

Our model was moderately sensitive to increasing the number of deaths due to DKA at diagnosis (the cost of screening increased from £3.17 to £7.28), so obtaining better information on this model parameter would be useful.

It would be useful to develop an economic model of T1D that appropriately includes the incidence of diabetes-related complications during childhood. Our approach in this project of not allowing diabetes-related complications was simple and may have been inaccurate. However, this gap will likely require the development of new epidemiological risk equations for diabetes-related complications in T1D children.

If teplizumab or other agents are approved to delay T1D in children, the available information should be included in this analysis. However, if these are completely new products to the

UK market, it is likely that they will be priced to capture the benefits obtained by using the treatments. This impact is likely to be small in terms of the cost-effectiveness of screening T1D. However, they could be essential for designing a screening program for T1D, as they would give children who test positive for treatment. This would likely increase the acceptability of screening for T1D among parents.

Other literature

There have been two previous analyses of T1D screening in children. There was an analysis by Karl *et al.* that conducted an analysis of the costs of screening in the Fr1da study by statistically analysing cost data collected in FRIDA and from routine sources in Germany³⁹. This was a within study costing of the Fr1da data and they found that screening for T1D as implemented in Fr1da cost €28.17 per child screened. There will be some differences between the German and English/Welsh settings of the Fr1da study and our analysis; however, if we can establish that there are some long-term benefits of screening, then it may be cost-effective to screen young children (four years old) for T1D. There was an analysis by McQueen *et al.* In the US setting, McQueen *et al.* found that avoiding DKA events alone would not result in cost-effective in the US setting. The model they used was an initial state transition up to age 30, which only tracked if children developed T1D and if they died, and a lifetime simulation model after age 30 to track the incidence of complications associated with T1D over children's lifetimes. This is similar to our result, albeit with the US having a higher maximum acceptable ICER generally than England and Wales, they found that screening could be cost-effective with only an HbA1c improvement of 0.1% over a lifetime⁴⁰. This again, is similar to our results. A recent review by Rewers, found similar results in that DKA prevention alone would not be sufficient to make screening for T1D worthwhile⁴¹. However, Rewers also made a point that societal costs, such as productivity and quality of life of the parents when their child is diagnosed would be additional economic benefits to those gained directly by the children with T1D with regards to their health⁴¹.

Conclusions

If screening for T1D can only prevent DKA at diagnosis, it would be very difficult to design a screening program that could be economically viable, as we would need it to cost £3 per child screened. If other benefits can be associated with screening, in particular, forming part of a relatively low-cost program to delay the onset of T1D, then this cost rises and designing a cost-effective screening program becomes more likely. Conducting further research to establish whether preventing DKA at diagnosis has long-term benefits for children with T1D is also a key area for future research.

Data availability statement

Our model is available at doi: <https://doi.org/10.15131/shef.data.29078807.v1> as an Excel macro-enabled workbook, under a CC-BY-4.0 licence⁴². If future versions of Excel break the functionality of the model, a zip folder is also provided containing each worksheet as a .csv file and macro to run the scenario analyses .txt file.

References

1. National Paediatric Diabetes Audit. Report on care and outcomes 2023/24. 2025. [Reference Source](#)
2. Royal College of Paediatric and Child Health Audits: National Paediatric Diabetes Audit (NPDA) Hospital admissions and complications reports 2011–2020. 2023; Last Accessed 31st January 2025. [Reference Source](#)
3. Cameron FJ, Scratch SE, Nadebaum C, *et al.*: Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. *Diabetes Care*. 2014; 37(6): 1554–62. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Duca LM, Wang B, Rewers M, *et al.*: Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. *Diabetes Care*. 2017; 40(9): 1249–55. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Nathan DM, DCCT/EDIC Research Group: The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. *Diabetes Care*. 2014; 37(1): 9–16. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Insel RA, Dunne JL, Atkinson MA, *et al.*: Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care*. 2015; 38(10): 1964–74. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Familial risk of type 1 diabetes in European children. The Eurodiab Ace Study Group and The Eurodiab Ace Substudy 2 Study Group. *Diabetologia*. 1998; 41(10): 1151–6. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Ziegler AG, Kick K, Bonifacio E, *et al.*: Yield of a Public health screening of children for Islet Autoantibodies in Bavaria, Germany. *JAMA*. 2020; 323(4): 339–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Elding Larsson H, Vehik K, Bell R, *et al.*: Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. *Diabetes Care*. 2011; 34(11): 2347–52. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Barker JM, Goehrig SH, Barriga K, *et al.*: Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. *Diabetes Care*. 2004; 27(6): 1399–404. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Hummel S, Carl J, Friedl N, *et al.*: Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. *Diabetologia*. 2023; 66(9): 1633–42. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. UK National Screening Committee: Criteria for a population screening programme. 2024; (accessed 17th January 2025). [Reference Source](#)
13. Royal College of Paediatric and Child Health Audits: National paediatric diabetes audit annual report 2019–20 care processes and outcomes. Appendix 1: Full Audit analysis. 2023.
14. National Institute for Health and Care Excellence: NICE health technology evaluations: the manual. NICE process and methods [PMG36]. 2023. [Reference Source](#)
15. Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQol Group. *Ann Med*. 2001; 33(5): 337–43. [PubMed Abstract](#) | [Publisher Full Text](#)
16. Herdman M, Gudex C, Lloyd A: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011; 20(10): 1727–36. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Dolan P: Modeling valuations for EuroQol health states. *Med Care*. 1997; 35(11): 1095–108. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Jones K, Weatherly H, Birch S, *et al.*: Unit costs of health and social care 2022. 2023. [Publisher Full Text](#)
19. Office for National Statistics: National life tables, United Kingdom, period expectation of life, based on data for the years 2018–2020. [Reference Source](#)
20. Hernández Alava M, Pudney S, Wailoo A: Estimating EQ-5D by age and sex for the UK. NICE DSU Report, 2022. [Reference Source](#)
21. Thokala P, Kruger J, Brennan A, *et al.*: Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. *Diabet Med*. 2014; 31(4): 477–86. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Royal College of Paediatric and Child Health Audits: Report on hospital admissions of children and young people with diabetes, 2015–2020. 2023. [Reference Source](#)
23. Royal College of Paediatric and Child Health Audits: Appendices to the NPDA report on hospital admissions of children and young people with diabetes 2015–20. 2023. [Reference Source](#)
24. NHS England: National Schedule of NHS costs 2020/21. 2022; Last Accessed 19th February 2025. [Reference Source](#)
25. Pollard DJ, Brennan A, Dixon S, *et al.*: Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial. *BMJ Open*. 2018; 8(4): e016766. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Winkley K, Upsher R, Stahl D, *et al.*: Psychological interventions to improve self-management of Type 1 and Type 2 Diabetes: a systematic review. *Health Technol Assess*. 2020; 24(28): 1–232. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Peasgood T, Brennan A, Mansell P, *et al.*: The impact of diabetes-related complications on preference-based measures of Health-Related Quality of Life in adults with Type 1 Diabetes. *Med Decis Making*. 2016; 36(8): 1020–33. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. National Institute for Health and Care Excellence: Type 1 Diabetes in adults: diagnosis and management. NICE guideline [NG17]. 2025; Last Accessed 26th February 2025. [Reference Source](#)
29. National Institute for Health and Care Excellence: Hybrid closed loop systems for managing blood glucose levels in Type 1 Diabetes. Final Appraisal Determination Committee Papers. Evidence Assessment Group addendum, 2023; Last Accessed: 10th April 2025. [Reference Source](#)
30. Asgharzadeh A, Patel M, Connock M, *et al.*: Hybrid closed loop systems for managing blood glucose levels in Type 1 Diabetes. 2022; Last Accessed 10th April 2025. [Reference Source](#)
31. Curtis L, Burns A: Unit costs of health and social care 2020. Canterbury: University of Kent, 2020. [Publisher Full Text](#)
32. Hammer M, Lammert M, Mejias SM, *et al.*: Costs of managing severe hypoglycaemia in three European countries. *J Med Econ*. 2009; 12(4): 281–90. [PubMed Abstract](#) | [Publisher Full Text](#)
33. Karges B, Prinz N, Placzek K, *et al.*: A comparison of familial and sporadic Type 1 Diabetes among young patients. *Diabetes Care*. 2021; 44(5): 1116–1124. [PubMed Abstract](#) | [Publisher Full Text](#)
34. Lundgren M, Jonsdottir B, Elding Larsson H, *et al.*: Effect of screening for Type 1 Diabetes on early metabolic control: the DiPiS study. *Diabetologia*. 2019; 62(1): 53–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Gibb FW, Teoh WL, Graham J, *et al.*: Risk of death following admission to a UK hospital with Diabetic Ketoacidosis. *Diabetologia*. 2016; 59(10): 2082–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. McCarroll Z, Townson J, Pickles T, *et al.*: Cost-effectiveness of home versus hospital management of children at onset of Type 1 Diabetes: the DECIDE randomised controlled trial. *BMJ Open*. 2021; 11(5): e043523. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. National Institute for Health and Care Excellence: Teplizumab for delaying the onset of stage 3 Type 1 Diabetes in people 8 years and over with stage 2 Type 1 Diabetes [ID6259]. 2024; Last Accessed 4th February 2025. [Reference Source](#)
38. National Institute for Health and Care Excellence: Hybrid closed loop systems for managing blood glucose levels in Type 1 Diabetes. TA 943. Committee Discussion, 2023; Last Accessed 10th April 2024. [Reference Source](#)
39. Karl FM, Winkler C, Ziegler AG, *et al.*: Costs of public health screening of children for presymptomatic Type 1 Diabetes in Bavaria, Germany. *Diabetes Care*. 2022; 45(4): 837–844. [PubMed Abstract](#) | [Publisher Full Text](#)
40. McQueen RB, Geno Rasmussen C, Waugh K, *et al.*: Cost and cost-effectiveness of large-scale screening for Type 1 Diabetes in Colorado. *Diabetes Care*. 2020; 43(7): 1496–1503. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Rewers M: Health economic considerations of screening for early Type 1 Diabetes. *Diabetes Obes Metab*. 2025. [PubMed Abstract](#) | [Publisher Full Text](#)
42. Pollard D, Brennan A: An economic model in excel of screening for Type 1 Diabetes in the UK. In: The University of Sheffield, 2025. <http://www.doi.org/10.15131/shef.data.29078807>